iTolerance, Inc., an early-stage regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression, and Northway Biotech, an end-to-end biologics CDMO, entered into a partnership agreement for the manufacture of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the iTOL-100 platform technology. The SA-FasL fusion protein has shown great potential in preclinical studies, establishing durable, localized immune tolerance, and enabling implanted tissue, organoid, or cell therapy to function as a viable replacement for damaged native cells.
BOSTON, May 9, 2022 /PRNewswire/ -- Northway Biotech, a leading contract development and manufacturing organization (CDMO) based out of Vilnius, Lithuania, recently welcomed an international delegation of ministers for a tour of its soon-to-open Waltham, Mass.-based facility. The 30,000 square-foot, state-of-the-art facility will include R&D labs for microbial and mammalian cell line development, upstream and downstream process development, processes establishment and analytical support, and is slated to create an anticipated 50 new jobs.
Immutep Limited, a biotechnology company, announces that it has signed a Manufacturing Service Agreement (MSA) with Northway Biotech, an end-to-end biopharmaceutical CDMO, to manufacture IMP761 ahead of clinical testing.
To manufacture novel binding immunoglobulin protein, ‘1805, to support phase 2 trials in rheumatoid arthritis and uveitis.